MedTrace Logo

Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy

NCT00125437 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2009-07-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether a larger dose of the aldosterone antagonist spironolactone combined with a lower dose of an ACE inhibitor is more effective in reverse left ventricular remodeling in severe congestive heart failure in patients with nonischemic cardiomyopathy.

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

spironolactone

Sponsors & Collaborators

  • Hebei Medical University

    lead OTHER

Principal Investigators

  • Kunshen Liu, M.D. · The First Hospital of Hebei Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2009-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00125437 on ClinicalTrials.gov